Table 2 Pulmonary function test (FEV1/ΔFEV1 and FVC/ΔFVC) of each group during and after FGF-2 treatment in the clinical trial

From: The role of FGF-2 in smoke-induced emphysema and the therapeutic potential of recombinant FGF-2 in patients with COPD

 

FEV1 (%)

ΔFEV1 (%)

FVC (%)

ΔFVC (%)

Control

FGF-2

Control

FGF-2

Control

FGF-2

Control

FGF-2

T1

42.8 ± 9.7

49.7 ± 7.4

0.0 ± 0.0

0.0 ± 0.0

65.2 ± 10.9

74.2 ± 15.2

0.0 ± 0.0

0.0 ± 0.0

T7

46.6 ± 13.6

55.2 ± 5.3

3.7 ± 6.6

5.5 ± 7.8

66.0 ± 17.7

76.3 ± 9.9

0.9 ± 8.3

2.1 ± 14.7

T15

42.1 ± 12.5

52.3 ± 5.9

−0.7 ± 7.1

2.5 ± 8.7

62.4 ± 15.1

74.5 ± 11.3

−2.8 ± 7.5

0.3 ± 12.9

A4

45.4 ± 8.3

50.9 ± 6.8

2.5 ± 7.2

1.1 ± 10.1

66.3 ± 10.3

75.3 ± 8.5

1.1 ± 7.9

1.1 ± 14.6

  1. FEV1 forced expiratory volume in one second, FVC forced vital capacity, FGF-2 fibroblast growth factor-2, T1 1 day of treatment, T7 7 days of treatment, T15 15 days of treatment, A4 after 4 weeks of treatment
Back to article page